ArticleBMC infectious diseases2025
Dynamics of respiratory virus transmission in children during and after COVID-19 outbreak control in Baiyin, China.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Acute Severity Versus Long-term Morbidity: Uncoupling the Roles of RSV and HRV in Childhood Respiratory Disease.Open forum infectious diseases · 2026Article
- Three-stage interpretability analysis of influenza virus and meteorological correlation in Jiuquan City, 2016-2025: SARIMAX + TreeSHAP.Frontiers in cellular and infection microbiology · 2026Article
- Pathogen profiles and co-detection characteristics of acute respiratory infections based on active surveillance in a large district of southern China.Frontiers in public health · 2026Article
- A study on the climate-driven spatiotemporal dynamics of influenza in Lanzhou spanning the COVID-19 era.Frontiers in cellular and infection microbiology · 2026Article
- Epidemiological trends and climate-driven dynamics of children respiratory infections in Lanzhou, China: a multi-pathogen time-series analysis.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeWe aimed to study the changes in respiratory virus detection rates during the control of the COVID-19 outbreak and to elucidate possible epidemiologic disturbances after the lifting of control measures.
methodsSevere acute respiratory infection (SARI) specimens were collected from hospitalized children in Baiyin, China, from 2021 to 2023. We conducted real-time fluorescence quantitative PCR (RT-qPCR) to detect various respiratory viruses, including influenza virus (IFV), human respiratory syncytial virus (HRSV), human rhinovirus (HRV), human parainfluenza virus (HPIV), human metapneumovirus (HMPV), human adenovirus (HADV), enterovirus (EV), and human coronavirus (HCoV). The results were statistically analyzed using SPSS 26.0 software.
resultsA total of 1353 nasopharyngeal swab specimens were collected from children with SARI between 2021 and 2023. The male-to-female ratio of 1.49:1, the total virus detection rate of 33.85% (458/1353). Data were analyzed by comparing two distinct periods: before the lifting of the COVID-19 control measures (January 1, 2021 - December 6, 2022) and after the lifting of the control measures (December 7, 2022 - December 31, 2023). During the three-year study period, there was no significant difference in the detection rate of pathogen positivity between the ≤ 1 year (OR: 0.986, 95% CI: 0.960-1.013) and 1-3 years (OR: 1.018, 95% CI: 0.997-1.060) age groups (P > 0.05). However, there were significant differences in pathogen positivity rates between the 3-6 years (OR: 1.097, 95% CI: 1.049-1.146) and > 6 years (OR: 1.099, 95% CI: 1.063-1.138) age groups (P < 0.05). Significant differences in pathogen positivity rates were observed between male (OR: 1.293, 95% CI: 1.156-1.445) and female (OR: 1.354, 95% CI: 1.157-1.583) children (P < 0.05). The positive detection rates for various viruses showed a decreasing trend in January and February 2023; however, IFV showed a significant rebound in 2023. Following the lifting of COVID-19 control measures, the overall positive detection rate for respiratory viruses increased significantly from 27.84 to 45.03% (OR: 1.313, 95% CI: 1.198-1.438) (P < 0.05). Prior to the lifting of control measures, the ranking of positive detection rates for respiratory viruses in children was as follows: HPIV > HRSV > HADV > HRV > HMPV > EV > HCOV > influenza virus (IFV). After the measures were lifted, the order was as follows: EV > IFV > HADV > HCOV > HPIV > HRV > HMPV > HRSV. The peak detection periods for HRV, HMPV, HADV, and EV shifted to later time points compared to those before the measures were lifted. After the lifting of control measures, the positive detection rates of IFV (OR: 1.090, 95% CI: 1.059-1.122), EV (OR: 1.102, 95% CI: 1.064-1.141), HCOV (OR: 1.043, 95% CI: 1.017-1.070), and HADV (OR: 1.028, 95% CI: 0.999-1.059) all significantly increased (P < 0.05); HRV (OR: 1.019, 95% CI: 0.994-1.044) and HMPV (OR: 1.010, 95% CI: 0.989-1.032) showed non-significant increases in positive detection rates (P > 0.05); HRSV (OR: 0.965, 95% CI: 0.946-0.985) was significantly reduced (P < 0.05), while the positive detection rate for HPIV (OR: 0.971, 95% CI: 0.943-1.001) showed no significant decrease(P > 0.05).
conclusionsThese findings help clarify that social interventions can influence the prevalence of respiratory viruses in children during unique historical periods. The implementation of COVID-19 control measures may have curbed the spread of respiratory viruses in children during the study period. After the lifting of control measures, monitoring of respiratory pathogens must be strengthened to reduce the harm caused by respiratory viruses to children's health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.